retatrutide type 2 diabetes phase 2 trial

retatrutide type 2 diabetes phase 2 trial In the 3 TRANSCEND-T2D-1 trial, patients with experienced: ✓ Up to 2% A1C reduction ✓ 90% achieved an A1C <7% ✓ 85% achieved an A1C <6.5% ✓ 46% The data just dropped —

Name: retatrutide type 2 diabetes phase 2 trial In the 3 TRANSCEND-T2D-1 trial, patients with experienced: ✓ Up to 2% A1C reduction ✓ 90% achieved an A1C <7% ✓ 85% achieved an A1C <6.5% ✓ 46% The data just dropped —
Brand: www.choicedeals.com
SKU: 50025279781
Price: 23.03 USD
Availability: InStock
Rating: 4.2862 (9 reviews)

SKU: 50025279781

4.3

EUR23.03 EUR59.03

Pay in 4 interest-free payments of $5.76 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 31 - Aug 5

Description

Why is the weight loss journey difficult

Only 8% of participants experienced minimal response (under 5% loss)

With that caveat, here is what the published Phase 3 data say at peak dose, in adults with obesity and without diabetes: The roughly 6-percentage-point gap between retatrutide and tirzepatide at peak dose, sustained across more than 2,000 participants, is the data point payers and prescribers will spend the next year arguing about